U.S. FDA Arthritis Advisory Committee Votes On Cimzia® (certolizumab pegol) For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis
Axial spondyloarthritis patients treated with certolizumab pegol reported improvements in pain, fatigue and physical function, and increased workplace and household productivity
